- Home
- QLYS vs VERA Comparison
QLYS vs VERA Comparison
Compare QLYS & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QLYS | VERA |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.9B |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QLYS | VERA |
|---|---|---|
| Price | $90.38 | $40.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $136.00 | $81.30 |
| AVG Volume (30 Days) | 538.1K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.99 | N/A |
| EPS | ★ 5.44 | N/A |
| Revenue | ★ $321,607,000.00 | N/A |
| Revenue This Year | $9.96 | N/A |
| Revenue Next Year | $7.15 | $416.83 |
| P/E Ratio | $16.52 | ★ N/A |
| Revenue Growth | ★ 15.32 | N/A |
| 52 Week Low | $85.14 | $18.53 |
| 52 Week High | $155.47 | $56.05 |
Technical Indicators
Market Signals| Indicator | QLYS | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 33.69 | 47.01 |
| Support Level | $85.14 | $37.36 |
| Resistance Level | $102.25 | $43.21 |
| Average True Range (ATR) | 3.90 | 2.51 |
| MACD | 0.39 | 0.18 |
| Stochastic Oscillator | 10.71 | 50.58 |
Price Performance
Historical ComparisonAbout QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.